United States Biotechnology & Medical Research

Replimune Group Inc (REPL)

Track

Over the last 90 days, Replimune Group Inc. has seen significant insider selling, with a net value of -$474,147. Executives accounted for -$384,449 of this net selling. A total of 8 transactions were recorded, all of which were sales, indicating a net negative insider sentiment. The stock has seen a 24.1% price increase over the same period.
Stock chart
Ticker: REPL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Sarchi Christopher
Chief Commercial Officer
1 sale — total 100,000 USD
Planned sale 1 Jun 2026
Value US$756,597.45 | Price 365.20 | Shares 16,617
Sale 18 May 2026
Value US$3,577,132.41 | Price 71.21 | Shares 98,804
Sale 18 May 2026
Value US$100,000.00 | Price 5.08 | Shares 1,000
Sale 18 May 2026
Value US$100,000.00 | Price 5.08 | Shares 1,000
Sale 18 May 2026
Value US$100,000.00 | Price 5.08 | Shares 1,000
Sale 18 May 2026
Value US$100,000.00 | Price 5.08 | Shares 1,000
Sale 18 May 2026
Value US$100,000.00 | Price 5.08 | Shares 1,000
Planned sale 2 Apr 2026
Value US$52,065.00 | Price 8.01 | Shares 6,500
Proposed sale 2 Apr 2026
Value US$142,450.00 | Price 7.70 | Shares 18,500
Sale 9 Dec 2025
Value US$32,957.60 | Price 10.40 | Shares 3,169
Proposed sale 9 Dec 2025
Value US$32,842.00 | Price 10.38 | Shares 3,164
Planned sale 2 Dec 2025
Value US$111,300.00 | Price 11.13 | Shares 10,000
Proposed sale 2 Dec 2025
Value US$111,303.00 | Price 11.13 | Shares 10,000
Sale 17 Nov 2025
Value US$65,956.80 | Price 9.10 | Shares 7,248
Sale 17 Nov 2025
Value US$47,392.80 | Price 9.10 | Shares 5,208
Sale 15 Aug 2025
Value US$49,156.98 | Price 5.37 | Shares 9,154
Sale 20 May 2025
Value US$30,179.45 | Price 8.05 | Shares 3,749
Sale 20 May 2025
Value US$26,460.35 | Price 8.05 | Shares 3,287
Sale 20 May 2025
Value US$260,168.74 | Price 8.06 | Shares 32,279
Sale 20 May 2025
Value US$64,093.12 | Price 8.06 | Shares 7,952
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-03 2026-06-01 PlS Planned sale
3.1
Sarchi Christopher

Chief Commercial Officer

Officer
16,617 -22.6%
365.20
US$756,597 		16,617 -22.6% 365.20 US$756,597
2026-05-20 2026-05-18 S Sale
2.6
Hill Emily Luisa

Chief Financial Officer

Officer
98,804 -7.9%
71.21
US$3,577,132 		98,804 -7.9% 71.21 US$3,577,132
2026-05-20 2026-05-18 S Sale
1.5
Schwendenman Andrew

Chief Accounting Officer

Officer
45,830 -28.7%
380.53
US$4,738,057 		45,830 -28.7% 380.53 US$4,738,057
2026-05-20 2026-05-18 S Sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
1,000 -4.8%
5.08
US$100,000 		1,000 -4.8% 5.08 US$100,000
2026-05-20 2026-05-18 S Sale
3.1
Sarchi Christopher

Chief Commercial Officer

Officer
1,000 -4.3%
5.08
US$100,000 		1,000 -4.3% 5.08 US$100,000
2026-05-20 2026-05-18 S Sale
2.1
Astley-Sparke Philip
Non-Executive Director
1,000 -1.2%
5.08
US$100,000 		1,000 -1.2% 5.08 US$100,000
2026-05-20 2026-05-18 S Sale
3.1
Xynos Konstantinos

Chief Medical Officer

Officer
1,000 -5.6%
5.08
US$100,000 		1,000 -5.6% 5.08 US$100,000
2026-04-06 2026-04-02 PlS Planned sale
3.1
Sarchi Christopher

Chief Commercial Officer

Officer
6,500 -4.1%
8.01
US$52,065 		6,500 -4.1% 8.01 US$52,065
2026-04-02 2026-04-02 PrS Proposed sale
3.1
Christopher Sarchi

Officer

Officer
18,500
7.70
US$142,450 		18,500 7.70 US$142,450
2025-12-11 2025-12-09 S Sale
3.6
Dhingra Kapil
Non-Executive Director
3,169 -100.0%
10.40
US$32,958 		3,169 -100.0% 10.40 US$32,958
2025-12-09 2025-12-09 PrS Proposed sale
3.6
Kapil Dhingra

Director

Non-Executive Director
3,164
10.38
US$32,842 		3,164 10.38 US$32,842
2025-12-04 2025-12-02 PlS Planned sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
10,000 -2.9%
11.13
US$111,300 		10,000 -2.9% 11.13 US$111,300
2025-12-02 2025-12-02 PrS Proposed sale
1.8
Sushil Patel

Chief Strategy Officer

Officer
10,000
11.13
US$111,303 		10,000 11.13 US$111,303
2025-11-19 2025-11-17 S Sale
3.1
Xynos Konstantinos

Chief Medical Officer

Officer
7,248 -4.9%
9.10
US$65,957 		7,248 -4.9% 9.10 US$65,957
2025-11-19 2025-11-17 S Sale
3.1
Sarchi Christopher

Chief Commercial Officer

Officer
5,208 -4.1%
9.10
US$47,393 		5,208 -4.1% 9.10 US$47,393
2025-08-19 2025-08-15 S Sale
2.6
Hill Emily Luisa

Chief Financial Officer

Officer
9,154 -6.4%
5.37
US$49,157 		9,154 -6.4% 5.37 US$49,157
2025-05-22 2025-05-20 S Sale
3.1
Sarchi Christopher

Chief Commercial Officer

Officer
3,749 -2.8%
8.05
US$30,179 		3,749 -2.8% 8.05 US$30,179
2025-05-22 2025-05-20 S Sale
1.5
Schwendenman Andrew

Chief Accounting Officer

Officer
3,287 -4.6%
8.05
US$26,460 		3,287 -4.6% 8.05 US$26,460
2025-05-22 2025-05-20 S Sale
2.1
Astley-Sparke Philip
Non-Executive Director
32,279 -2.2%
8.06
US$260,169 		32,279 -2.2% 8.06 US$260,169
2025-05-22 2025-05-20 S Sale
3.1
Xynos Konstantinos

Chief Medical Officer

Officer
7,952 -5.1%
8.06
US$64,093 		7,952 -5.1% 8.06 US$64,093
Explore more

More insider trading research around Replimune Group Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America